Following an application from Efamol Ltd, submitted pursuant to Article 14(1)(b) of Regulation (EC) No 1924/2006, the Authority was required to deliver an opinion on a health claim related to the effects of Efalex® on brain development and function (Question No EFSA-Q-2008-318) [The EFSA Journal (2008) 898, pp. 1-2.]. The claim proposed by the applicant was worded as follows: ‘Efalex® may help maintain and support brain development and function’.
Recital 29, Commission Regulation (EC) No 1024/2009 of 29 October 2009 on the authorisation and refu…
In forcesince 29 Oct 2009